JapanStake
Pharmaceutical · Fiscal year end Jun 30

TAUNS Laboratories, Inc.

197A

株式会社タウンズ

FIGI BBG002PD9TF0197A.T197A JPCorp. no. 4010001175101

Latest half-year results

First half · fiscal year to 2026-06 · filed 2026-02-13

For the first half of the fiscal year to 2026-06: Revenue ¥8.3 billion (-30.9% YoY), Ordinary income ¥3.1 billion (-51.8% YoY), Net income ¥2.1 billion (-56.0% YoY).

This periodYear on year
Revenue¥8.3bn-30.9%
Ordinary profit¥3.1bn-51.8%
Net profit to owners¥2.1bn-56.0%

From the securities report on EDINET, which states no forecast. History via /v1/companies/197A/earnings-releases.

Financials

Japan GAAP · non-consolidated · fiscal year to 2026-06-30
Revenue
¥14.4bn
Net income
¥5.5bn
ROE
29.8%
Equity ratio
43.5%
Dividend / share
¥28
Employees
350
Revenue · ¥bn
FY2022: ¥17.5bn 17.5 FY2022FY2023: ¥15.7bn 15.7 FY2023FY2024: ¥18.4bn 18.4 FY2024FY2025: ¥18.6bn 18.6 FY2025FY2026: ¥14.4bn 14.4 FY2026
Net income · ¥bn
FY2022: ¥4.5bn 4.48 FY2022FY2023: ¥3.0bn 3.03 FY2023FY2024: ¥5.8bn 5.77 FY2024FY2025: ¥6.3bn 6.32 FY2025FY2026: ¥5.5bn 5.5 FY2026
Fiscal yearRevenueNet incomeTotal assetsNet assetsROEEPSOperating CF
2026-06-30¥14.4bn¥5.5bn¥44.6bn¥19.4bn29.8%¥52.28−¥2.8bn
2025-06-30¥18.6bn¥6.3bn¥36.5bn¥17.4bn40.7%¥62.07¥6.8bn
2024-06-30¥18.4bn¥5.8bn¥29.3bn¥13.7bn52.2%¥57.74¥9.9bn
2023-06-30¥15.7bn¥3.0bn¥18.3bn¥8.5bn38.3%¥30.35−¥3.2bn
2022-06-30¥17.5bn¥4.5bn¥20.3bn¥7.4bn74.6%¥44.81¥10.7bn

Indicators

Computed by us from filings · fiscal year to 2026-06-30
MetricValuePercentile among listed companies
ROE, %29.895.7
Ordinary margin0.275195.5
Equity ratio, %43.531.9
Revenue growth-0.22862.2
Net income growth-0.129926.4
Operating cash flow / assets-0.06336.8
Policy-uncertainty measure0.00 Share of the report's text discussing policy-related uncertainty, by policy area. Proprietary text method.
Ownership activity 0 filer(s) stated they may make proposals in 365 days; 0 new 5% holder(s) in 180 days; net stake change −2.89pt in 90 days; 0.0% held by other listed companies.

Results wording balance: -0.33. Proprietary text method; it describes the wording only and does not interpret context.

Interest example: if all ¥21.3bn of reported debt repriced by 50 basis points, a year's interest would rise by ¥106m. Our arithmetic only, not a forecast: fixed-rate debt and hedges are ignored.

Via /v1/companies/197A/indicators. Descriptive figures, not a rating and not investment advice.

From other filings

As the company states them
Internal control, 2026-09-24: see filing 上記の評価の結果、当事業年度末時点において、当社の財務報告に係る内部統制は有効であると判断しました。 Filing

Segments, votes and tender offers

Stated in EDINET filings
Latest voting result: 2026-09-25 · 剰余金処分の件 · passed. /v1/companies/197A/voting

Ownership changes

All companies →

Trades by 5% holders

From the 60-day trade tables in 5% reports
¥430¥430¥430 2024-06-202024-06-20 2024-06-20 · sold 17,715,800 @ ¥430.1 · CJP III GP Ltd.2024-06-20 · sold 109,100 @ ¥430.1 · CCP Japan Ltd2024-06-20 · sold 1,304,400 @ ¥430 · individual filer
Bought SoldHover a dot for the trade
HolderPeriodNet sharesNet % of sharesAvg. filed priceRange
individual filer2024-06-20 – 2025-12-04-1,304,400−1.27pt¥430¥430–430
CCP Japan Ltd2024-06-20 – 2024-06-20-109,100−0.11pt¥430.1¥430–430
CJP III GP Ltd.2024-06-20 – 2024-06-20-17,715,800−17.72pt¥430.1¥430–430

Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/197A/trades.

5% filings

Large shareholding reports on 197A
FiledFilerStakeChangeStated purpose
2026-10-19CJP III GP Ltd.39.29%−2.89ptpure investment
2025-12-25CJP III GP Ltd.39.44%−2.74ptpure investment
2025-12-24CJP III GP Ltd.39.44%−2.74ptpure investment
2025-12-19individual filer29.63%0.00pt—
2025-12-04individual filer29.63%−0.03pt—
2025-12-02individual filer29.66%0.00pt—
2025-11-14individual filer29.66%−0.01pt—
2025-11-05individual filer29.67%0.00pt—
2025-10-14individual filer29.69%−0.64pt—
2025-10-14individual filer29.67%−0.02pt—

Cross-shareholdings

From the annual report's status of shareholdings
Listed strategic holdings
1 issues
Book value
¥13m
Sold in the year
— — issues
Bought in the year
¥1m 1 issues
Mutual, both reports
0
Held by listed cos.
0
HoldsBook valueShares vs. prior yearMutual
WAKAMOTO PHARMACEUTICAL CO.,LTD. 4512¥13m+9.8%no

Purposes, all holdings and mutual flags via /v1/companies/197A/cross-holdings. Share changes include stock splits.

Major shareholders

As of fiscal year end 2026-06-30
ShareholderSharesRatio
CITIC CAPITAL JAPAN PARTNERS Ⅲ, L.P.41,707,85639.09%
individual holder31,232,21729.27%
野村信託銀行株式会社(投信口)889,5000.83%
株式会社メディカル・コンシェルジュ700,0000.65%
日本マスタートラスト信託銀行株式会社(信託口)345,1000.32%
individual holder343,5000.32%
CCJP Ⅲ CO-INVESTMENT, L.P.256,9570.24%
株式会社日本カストディ銀行(信託口)222,9000.20%
individual holder213,4000.20%
individual holder162,8000.15%

U.S. funds holding 197A

SEC Form N-PORT, reports to 2026-07-31

12 U.S. funds held 232,400 shares worth $0.7m.

FundSharesValue% of fundAs of
WisdomTree Japan SmallCap Dividend Fund
WisdomTree Trust
84,100$0.2m0.065%2026-06-30
WisdomTree International High Dividend Fund
WisdomTree Trust
45,000$0.1m0.021%2026-06-30
Dimensional International Core Equity 2 ETF
Dimensional ETF Trust
19,000$0.1m0.000%2026-07-31
WisdomTree International Equity Fund
WisdomTree Trust
18,900$0.1m0.008%2026-06-30
THE JAPANESE SMALL COMPANY SERIES
DFA INVESTMENT TRUST CO
17,500$0.1m0.001%2026-07-31

Up to 25 funds per stock via the API.

Get this as JSON

GET /v1/companies/197A
GET /v1/companies/197A/financials
GET /v1/companies/197A/details
GET /v1/companies/197A/segments
GET /v1/companies/197A/voting
GET /v1/companies/197A/tender-offers
GET /v1/companies/197A/indicators
GET /v1/companies/197A/earnings-releases
GET /v1/events?ticker=197A
GET /v1/companies/197A/trades         
GET /v1/companies/197A/cross-holdings 
GET /v1/companies/197A/brief          

Plans from $9 a month · Documentation